Format

Send to

Choose Destination
J Pediatr Pharmacol Ther. 2006 Apr;11(2):92-100. doi: 10.5863/1551-6776-11.2.92.

An open label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources.

Author information

1
Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, Pennsylvania;

Abstract

OBJECTIVE:

To compare calfactant (CA) and poractant alfa (PA) administration traits, short-term clinical responses, and resource use in the neonatal respiratory distress syndrome (RDS) setting.

METHODS:

An open label series of 277 (213 PA and 64 CA) infants was evaluated for 445 administrations. Registered respiratory therapists collected patient, surfactant administration, and postadministration clinical data. Economic analysis involved labor costs of surfactant administration and usage, wastage, and product average wholesale price. Analysis utilized the Mann-Whitney rank sum test for differences in administration time and either the chi-square or Fisher's exact test for categorical variables.

RESULTS:

PA had a statistically lower bedside administration time than CA (3.8 minutes vs. 5.3 minutes; P = .006) and a higher percentage of doses administered in less than five minutes (58.9% vs. 4.3%; P < .001). Doses administered per patient were similar (1.67 vs. 1.72). PA and CA were similar in time to recovery (81.4% vs. 74.3%), percent desaturation (24.8% vs. 26.7%), and bradycardia (3.8% vs. 8.5%). Reflux was significantly higher (13.2% vs. 3.5%; P < .001) with CA. Economic analyses found total administration costs per dose were $2.21 for PA and $3.08 for CA. Mean wastage costs were $141.21 for PA and $337.34 for CA (P < .001).

CONCLUSIONS:

PA appeared to utilize fewer neonatal intensive care unit resources than CA due to reduced administration time and less wastage of drug product. Future studies should more closely evaluate time, resource, wastage, and post-administrative clinical effects to fully assess the impact of surfactant products in this setting.

KEYWORDS:

calfactant; pharmacoeconomics; poractant alfa; respiratory distress syndrome; surfactant

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center